TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (TICIMEL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03293784 |
Recruitment Status :
Recruiting
First Posted : September 26, 2017
Last Update Posted : January 12, 2021
|
Sponsor:
Institut Claudius Regaud
Information provided by (Responsible Party):
Institut Claudius Regaud
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Actual Primary Completion Date : | December 6, 2019 |
Estimated Study Completion Date : | April 2023 |